H.C. Wainwright analyst Ed Arce raised the price target on AcelRx Pharmaceuticals (NASDAQ: ACRX) to $8.00 (from $7.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

Pre-Open Movers 10/15: (ACRX) (ABCD) (LLL) Higher; (SHLD) (NTRI) Lower (more...)October 15, 2018 9:22 AM Jefferies Upgrades AcelRx Pharmaceuticals (ACRX) to BuyOctober 15, 2018 6:09 AM AcelRx Pharma (ACRX) Confirms FDA Advisory Committee Recommends Approval of DSUVIA for Treatment of Moderate-To-Severe Acute PainOctober 12, 2018 4:16 PM FDA Advisory Committee Recommends Approval Of DSUVIA For The Treatment Of Moderate-To-Severe Acute PainOctober 12, 2018 4:15 PM